Cytokine gene polymorphisms in allergic contact dermatitis

Contact Dermatitis

Volumn 48, Issue 2, 2003, Pages 93-98

  Westphal, Götz A ^a   Schnuch, Axel ^a   Moessner, Rotraut ^a   König, Inke R ^b   Kränke, Birger ^c   Hallier, Ernst ^a   Ziegler, Andreas ^b   Reich, Kristian ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Gene polymorphism; Interleukin 1 ; Interleukin 6; Tumour necrosis factor

Indexed keywords

ALLERGEN; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTACT SENSITIZATION; ECZEMA; FEMALE; GENE LOCUS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; SKIN ALLERGY; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; AGE DISTRIBUTION; ALLELES; AUSTRIA; CASE-CONTROL STUDIES; CYTOKINES; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; INTERLEUKIN-1; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROBABILITY; RECEPTORS, INTERLEUKIN-1; REFERENCE VALUES; SEX DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242417518     PISSN: 01051873     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0536.2003.480208.x     Document Type: Article

References (44)

1. Schnuch A, Uter W, Geier J, Gefeller O. Epidemiology of contact allergy: an estimation of morbidity employing the clinical epidemiology and drug utilisation research (CEDUR) approach. Contact Dermatitis 2002: 47: 32-39.
2. Menné T, Holm N V. Genetic susceptibility in human allergic contact sensitization. Seminars Dermatol 1986: 5: 301-306.
3. Emtestam L, Carlsson B, Marcusson J A, Wallin J, Moller E. Specificity of HLA restricting elements for human nickel reactive T cell clones. Tissue Antigens 1989: 33: 531-541.
4. Emtestam L, Olerup O. On T-cell recognition of nickel as a hapten. Acta Derm Venereol 1996: 76: 344-347.
5. Moss C, Friedmann P S, Shuster S, Simpson J M. Susceptibility and amplification of sensitivity in contact dermatitis. Clin Exp Immunol 1985: 61: 232-241.
6. Merk H F, Jugert F K, Frankenberg S. Biotransformations in the skin. In: Marzulli, F N Maibach, H I, eds. Dermatotoxicology, 5th edn. pp. 61-73. Washington DC: Taylor & Francis, 1992.
7. Scholes E W, Pendlington R U, Sharma R K, Basketter D A. Skin metabolism of contact allergens. Toxicol In Vitro 1994: 8: 551-553.
8. Kimber I, Cumberbatch M, Dearman R J, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000: 142: 401-412.
9. Enk Ah, Angeloni V L, Udey MC, Katz S I. An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune response in skin. J Immunol 1993: 151: 2390-2398.
10. Kondo S, Pastore S, Fujisawa H, Shivji G M, McKenzie R C, Dinare Sauder D N. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995: 105: 334-338.
11. Shornick L P, De Togni P, Mariathasan S et al. Mice deficient in IL-1 beta manifest impaired contact hypersensitivity to trinitrochlorobenzone. J Exp Med 1996: 183: 1427-1436.
12. Hope J C, Campbell F, Hopkins S J. Deficiency of IL-2 or IL-6 reduces lymphocyte proliferation, but only IL-6 deficiency decreases the contact hypersensitivity response. Eur J Immunol 2000: 30: 197-203.
13. Schnuch A, Westphal G A, Müller M M, et al. Genotype and phenotype of N-acetyltransferase 2 (NAT-2) polymorphism in contact allergy patients. Contact Dermatitis 1998: 38: 209-211.
14. Westphal G A, Reich K, Schulz T G, Neumann Ch, Hallier E, Schnuch A. N-Acetyltransferases 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol 2000: 142: 1121-1127.
15. Westphal G A, Schnuch A, Schulz T G, et al. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Intern Arch Occup Environ Health 2000: 73: 384-388.
16. Morton N E, Collins A. Tests and estimates of allelic association in complex inheritance. Proc Natl Acad Sci USA 1998: 95: 11389-11393.
17. Uter W, Schnuch A, Geier J, Frosch P J. The information network of departments of dermatology (IVDK) in Germany. Eur J Dermatol 1998: 8: 36-40.
18. Fregert S. Manual of Contact Dermatitis, 2nd edn. Copenhagen: Munksgaard, 1981.
19. Miller S A, Dykes D D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1215-1217.
20. D'Alfonso S, Richiardi P M. A polymorphic variation in a putative regulation box of the TNFA promotor region. Immunogenetics 1994: 39: 150-154.
21. Wilson A G, de Vries N, Pociot F, di Giovine F S, van der Putte L B A, Duff G W. An allelic polymorphism within the human tumour necrosis factor a promotor region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med 1993: 177: 557-560.
22. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur J Clin Invest 1992: 22: 396-402.
23. Di Giovine F S, Takhsh E, Blakemore A I F, Duff G W. Single base polymorphism at -511 in the human interleukin-1β gene. Hum Mol Genet 1992: 1: 450.
24. Tarlow J K, Blakemore A I F, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86 base pair tandem repeat. Hum Genet 1993: 91: 403-404.
25. Santtila S, Savinainen K, Hurme M. Presence of the IL-1Ra allele: 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998: 47: 195-198.
26. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998: 102: 1369-1376.
27. Bioque G, Crusius J B A, Koutroubakis I, Bouma G. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995: 102: 379-383.
28. Day C P, Grove J, Daly A K, Stewart M W, Avery P J, Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 1998: 41: 430-434.
29. Chouchane L, Ahmed S B, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997: 80: 1489-1496.
30. Mehta C R, Patel N R, Gray R. On computing an exact confidence interval for the common odds ratio in several 2 × 2 contingency tables. J Am Star Assoc 1985: 80: 969-973.
31. Mansfield J C, Holden H, Tarlow J K, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994: 106: 637-642.
32. El-Omar E M, Carrington M, Chow Wh, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000: 404: 398-402.
33. Cumberbatch M, Dearman R J, Kimber I. Langerhans cells require signals from both tumour necrosis factor alpha and interleukin-1 beta for migration. Immunology 1997: 92: 388-395.
34. Rink L, Kirchner H. Recent progress in the tumor necrosis factor-α field. Int Arch Alelrgy Immunol 1996: 111: 199-209.
35. Kroeger K M, Abraham L J. Identification of an AP-2 element in the-323 to-285 region of the TNF-alpha gene. Biochem Mol Biol Int 1996: 40: 43-51.
36. Wilson A G, Symons J A, McDowell T L, McDevitt H O, Duff G W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997: 94: 3195-3199.
37. Kroeger K M, Carville K S, Abraham L J. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997: 34: 391-399.
38. McGuire W, Hill A V, Allsopp C E, Greenwood B M, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994: 371: 508-510.
39. Nadel S, Newport M J, Booy R, Levin M. Variation in the tumor necrosis factor alpha gene promotor region may be associated with death of menigococcal disease. J Infect Dis 1996: 174: 63-68.
40. Allen Mh, Wakelin Sh, Holloway D, Baadsgaard O, Barker J N W N, McFadden J. TNFalpha and IL-1 receptor antagonist gene polymorphisms in susceptibility to irritant contact dermatitis. Br J Dermatol 1998: 138: 201-205.
41. Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001: 116: 319-329.
42. McFadden J P, Basketter D A. Contact allergy, irritancy and 'danger'. Contact Dermatitis 2000: 42: 123-127.
43. Hohler T, Kruger A, Schneider PM, Schorf RE, Knor J, Rittner C, Meyer zum Büschenfelde K, Marker-Hermann E. TNF-alpha promotor polymorphism is associated with juvenile on set psoriasis and psoriatic arthritis. J Invest Dermatol 1997: 109: 562-565.
44. Reich K, Mössner R, König I R, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002: 118: 155-163.